Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclophosphamide
Drug ID BADD_D00549
Description Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Indications and Usage Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
Marketing Status approved; investigational
ATC Code L01AA01
DrugBank ID DB00531
KEGG ID D00287; D07760
MeSH ID D003520
PubChem ID 2907
TTD Drug ID D0CT9C
NDC Product Code 14335-360; 38779-0506; 10019-944; 10019-945; 10019-984; 58623-0024; 62559-931; 70121-1240; 0781-3233; 0781-3244; 10019-955; 51927-4871; 71052-223; 81955-0004; 43598-662; 50742-520; 69097-517; 70121-1239; 72572-085; 72572-087; 0781-3255; 10019-935; 10019-942; 51927-0221; 76339-191; 62332-619; 70121-1238; 54879-022; 55150-271; 62332-618; 69097-516; 70860-218; 42973-318; 10019-937; 76339-164; 50742-519; 51407-748; 72603-411; 10019-939; 65124-0003; 50742-521; 54879-021; 68001-564; 72603-326; 16714-857; 43598-661; 55150-270; 0054-0382; 10019-956; 10019-957; 51407-749; 51407-750; 68001-565; 0054-0383; 72572-083; 15308-0921; 10019-936; 57821-004; 16714-859; 68001-442; 68001-444; 72603-104; 10019-982; 82920-708; 16714-858; 46708-618; 68001-443; 10019-938; 10019-943; 57884-0022; 68554-0062; 43598-660; 46708-619
UNII 8N3DW7272P
Synonyms Cyclophosphamide | Sendoxan | B-518 | B 518 | B518 | Cyclophosphamide Anhydrous | Cyclophosphamide, (R)-Isomer | Cyclophosphamide, (S)-Isomer | Cytophosphane | Cyclophosphamide Monohydrate | Cytophosphan | Cytoxan | Endoxan | Neosar | NSC-26271 | NSC 26271 | NSC26271 | Procytox | (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate | Cyclophosphane
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 50-18-0
SMILES C1CNP(=O)(OC1)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neurotoxicity17.02.10.002; 12.03.01.011--Not Available
Neutropenia01.02.03.004--Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.001--Not Available
Obliterative bronchiolitis12.02.09.036; 10.02.01.096; 22.03.01.012--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oligomenorrhoea21.01.02.004; 05.05.01.011--Not Available
Oligospermia21.03.03.005--
Ovarian atrophy21.11.02.011; 05.05.01.018--Not Available
Ovarian disorder21.11.02.004--Not Available
Ovarian failure21.11.02.005; 05.05.01.012--Not Available
Pain08.01.08.004--
Palmar-plantar erythrodysaesthesia syndrome23.03.05.009; 17.02.07.009--
Palpitations02.11.04.012--
Pancreatitis acute07.18.01.002--Not Available
Pancytopenia01.03.03.003--Not Available
Paraesthesia17.02.06.005; 23.03.03.094--
Parosmia17.04.04.002; 22.04.03.007--Not Available
Pericardial effusion02.06.01.002--
Pericardial haemorrhage24.07.01.013; 02.06.01.003--Not Available
Pericarditis02.06.02.001--
Peripheral ischaemia24.04.03.002--
Phlebitis24.12.03.004; 12.02.01.002--
Platelet count decreased13.01.04.001--
Pleural effusion22.05.02.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Polyneuropathy17.09.03.012--Not Available
Polyuria20.02.03.002--Not Available
Pregnancy18.08.02.004--Not Available
Premature labour18.07.01.002--Not Available
Prurigo23.03.04.017--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene